| 2026-05-05 |
详情>>
股本变动：
变动后总股本5040.23万股
|
| 2026-05-05 |
详情>>
业绩披露：
2026年一季报每股收益-0.25美元,归母净利润-1254.4万美元,同比去年增长10.28%
|
| 2026-05-04 |
财报披露：
美东时间 2026-05-04 盘后发布财报
|
| 2026-04-22 |
股东大会：
将于2026-06-05召开股东大会
会议内容 ▼▲
- 1.To elect six directors;
2.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company and its subsidiaries for the year ending December 31, 2026;
3.To approve, on an advisory basis, the compensation of the named executive officers, as disclosed in our proxy statement for the Annual Meeting;
4.To approve an amendment to the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan to, among other things, increase the number of authorized shares under the plan;
5.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2026-04-21 |
详情>>
内部人交易：
SHELTON JERRELL股份增加104007.00股
|
| 2026-03-05 |
详情>>
业绩披露：
2023年年报每股收益-2.21美元,归母净利润-1.08亿美元,同比去年增长-137.33%
|
| 2026-03-05 |
详情>>
业绩披露：
2025年年报每股收益1.40美元,归母净利润7030.10万美元,同比去年增长157.27%
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益1.68美元,归母净利润8394.50万美元,同比去年增长182.24%
|
| 2025-08-12 |
详情>>
业绩披露：
2025年中报每股收益1.78美元,归母净利润8919.90万美元,同比去年增长188.42%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.28美元,归母净利润-1398.1万美元,同比去年增长33.09%
|
| 2025-04-25 |
股东大会：
将于2025-06-06召开股东大会
会议内容 ▼▲
- 1.To elect six directors;
2.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company and its subsidiaries for the year ending December 31, 2025;
3.To approve, on an advisory basis, the compensation of the named executive officers, as disclosed in our proxy statement for the Annual Meeting;
4.To approve, on an advisory basis, the preferred frequency of future advisory votes on the compensation of the named executive officers;
5.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2025-03-07 |
详情>>
业绩披露：
2024年年报每股收益-2.49美元,归母净利润-1.23亿美元,同比去年增长-14.1%
|
| 2025-03-07 |
详情>>
业绩披露：
2022年年报每股收益-0.93美元,归母净利润-4533.3万美元,同比去年增长84.02%
|
| 2025-03-05 |
复牌提示：
2025-03-05 09:30:16 停牌，复牌日期 2025-03-05 09:41:38
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.07美元,归母净利润-1.02亿美元,同比去年增长-136.3%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-2.05美元,归母净利润-1.01亿美元,同比去年增长-261.22%
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益-0.43美元,归母净利润-2089.5万美元,同比去年增长-175.88%
|
| 2024-04-03 |
股东大会：
将于2024-05-17召开股东大会
会议内容 ▼▲
- 1.To elect seven directors;
2.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company and its subsidiaries for the year ending December 31, 2024;
3.To approve, on an advisory basis, the compensation of the named executive officers, as disclosed in our proxy statement for the Annual Meeting;
4.To approve an amendment to the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan to increase the number of authorized shares under the plan;
5.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2023-03-31 |
股东大会：
将于2023-05-12召开股东大会
会议内容 ▼▲
- 1.To elect eight directors;
2.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company and its subsidiaries for the year ending December 31, 2023;
3.To approve, on an advisory basis, the compensation of the named executive officers, as disclosed in our proxy statement for the Annual Meeting;
4.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2022-03-18 |
股东大会：
将于2022-04-29召开股东大会
会议内容 ▼▲
- 1.To elect eight directors;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company and its subsidiaries for the year ending December 31, 2022;
3.To approve, on an advisory basis, the compensation of the named executive officers, as disclosed in our proxy statement for the Annual Meeting;
4.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-16 |
股东大会：
将于2021-04-30召开股东大会
会议内容 ▼▲
- 1.To elect eight directors;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company and its subsidiaries for the year ending December 31, 2021;
3.To approve, on an advisory basis, the compensation of the named executive officers, as disclosed in our proxy statement for the Annual Meeting;
4.To approve an amendment to the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan to increase the number of authorized shares under the plan;
5.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2020-04-03 |
股东大会：
将于2020-05-01召开股东大会
会议内容 ▼▲
- 1.To elect six directors
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company and its subsidiaries for the year ending December 31, 2020;
3.To approve, on an advisory basis, the compensation of the named executive officers, as disclosed in our Proxy Statement for the Annual Meeting;
4.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2019-04-03 |
股东大会：
将于2019-05-02召开股东大会
会议内容 ▼▲
- 1.To elect six directors;
2.To ratify the appointment of KMJ Corbin & Company LLP as the independent registered public accounting firm of the Company and its subsidiaries for the year ending December 31, 2019;
3.To approve, on an advisory basis, the compensation of the named executive officers, as disclosed in our Proxy Statement for the Annual Meeting;
4.To determine, on an advisory basis, the frequency with which the stockholders of the Company wish to have an advisory vote on the compensation of the named executive officers;
5.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2018-04-09 |
股东大会：
将于2018-05-17召开股东大会
会议内容 ▼▲
- 1.To elect five directors;
2.To ratify the appointment of KMJ Corbin & Company LLP as the independent registered public accounting firm of the Company and its subsidiaries for the year ending December 31, 2018;
3.To approve the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan;
4.To amend the Company’s Amended and Restated Articles of Incorporation to increase the number of authorized shares of the Company’s common stock from 50,000,000 shares to 100,000,000 shares (the “Authorized Shares Proposal”);
5.To approve, on an advisory basis, the compensation of the named executive officers, as disclosed in our Proxy Statement for the Annual Meeting;
6.To approve the adjournment of the meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the meeting to approve the Authorized Shares Proposal;
7.To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2017-08-11 |
股东大会：
将于2017-09-12召开股东大会
会议内容 ▼▲
- 1. To elect five directors;
2. To ratify the appointment of KMJ Corbin & Company LLP as the independent registered public accounting firm of the Company and its subsidiary for the year ending December 31, 2017;
3. To approve, on an advisory basis, the compensation of the named executive officers, as disclosed in our Proxy Statement for the Annual Meeting;
4. To transact such other business as may properly come before the meeting or any adjournment thereof.
|
| 2016-09-02 |
股东大会：
将于2016-09-21召开股东大会
会议内容 ▼▲
- (1)To elect five directors;
(2)To ratify the appointment of KMJ Corbin & Company LLP as the independent registered public accounting firm of the Company and its subsidiary for the fiscal year ending March 31, 2017;
(3)To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the potential issuance of more than 20% of the Company’s issued and outstanding common stock in connection with the Company’s warrant exchange offer transaction (the “Nasdaq Proposal”);
(4)To approve, on an advisory basis, the compensation of the named executive officers, as disclosed in our Proxy Statement for the Annual Meeting;
(5)To approve the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the meeting to approve the Nasdaq Proposal;
(6)To transact such other business as may properly come before the meeting or any adjournment thereof.
|